Cisplatin-induced Ototoxicity

1

Review clinical trials related to Cisplatin-induced Ototoxicity. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial

The purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy. Cisplatin is a highly effective chemotherapeutic agent but often leads to permanent hearing loss (ototoxicity) as a significant side effect. This study investigates whether the administration of NAC as an otoprotective agent can reduce or prevent the decline in hearing sensitivity, particularly at extended high frequencies, as measured by audiometry and distortion product otoacoustic emissions (DPOAE).

Participants needed: 40
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Siriraj HospitalUpdated: Jan 23, 2026Locations: 1
Eligibility criteria

Patients aged between 18 and 70 years [+5]

Patients diagnosed with Nasopharyngeal Carcinoma (CA nasopharynx). [+2]